Assumption 1: Affordability of Full Genomic Signature for Every Patient
The low cost of full genome sequencing may soon reach a price point at which every patient who consents to genetic testing will have a full genome in their health record. Genetics labs today frequently test for individual gene variations (e.g., markers for a risk of breast cancer or for inherited diseases like Huntington’s chorea). Soon, the cost of the full genome will be essentially the same as a few of these single genetic tests, causing the “standard” genetic test to become the full genome, potentially making the market for targeted testing obsolete, unless a high volume of patients choose to authorize only targeted and more limited sequencing. That scenario seems much less likely than the scenario in which full sequencing is performed whenever DNA testing is done. Today, reduced costs and simplified process make it much more likely to get a full electrolyte panel rather than just potassium and creatinine levels. The same process change is likely to occur with DNA testing.